Department of Internal Medicine, Medical College, Najran University, Najran, Saudi Arabia.
Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, PO Box 14132, Baghdad, Iraq.
Acta Neurol Belg. 2024 Apr;124(2):377-388. doi: 10.1007/s13760-023-02403-x. Epub 2023 Nov 2.
Alzheimer's disease (AD) is the most common type of dementia associated with amyloid beta (Aβ) deposition. Dysfunction of the neuronal clearance pathway promotes the accumulation of Aβ. The plasminogen-activating system (PAS) is controlled by various enzymes like tissue plasminogen activators (tPA). Neuronal tPA enhances the conversion of plasminogen to plasmin, which cleaves Aβ; this function is controlled by many inhibitors of PAS, including a plasminogen-activating inhibitor (PAI-1) and neuroserpin. Therefore, the objective of the present narrative review was to explore the potential role of tPA/neuroserpin in the pathogenesis of AD. PAI-1 activity is increased in AD, which is involved in accumulating Aβ. Progressive increase of Aβ level during AD neuropathology is correlated with the over-production of PAI-1 with subsequent reduction of plasmin and tPA activities. Reducing plasmin and tPA activities promote Aβ by reducing Aβ clearance. Neuroserpin plays a critical role in the pathogenesis of AD as it regulates the expression and accumulation of Aβ. Higher expression of neuroserpin inhibits the neuroprotective tPA and the generation of plasmin with subsequent reduction in the clearance of Aβ. These observations raise conflicting evidence on whether neuroserpin is neuroprotective or involved in AD progression. Thus, neuroserpin over-expression with subsequent reduction of tPA may propagate AD neuropathology.
阿尔茨海默病(AD)是最常见的与淀粉样蛋白β(Aβ)沉积相关的痴呆症。神经元清除途径的功能障碍促进了 Aβ的积累。纤溶酶原激活系统(PAS)受各种酶如组织型纤溶酶原激活物(tPA)的控制。神经元型 tPA 增强纤溶酶原向纤溶酶的转化,从而切割 Aβ;这一功能受许多 PAS 抑制剂的控制,包括纤溶酶原激活抑制剂(PAI-1)和神经丝氨酸蛋白酶抑制剂(neuroserpin)。因此,本综述的目的是探讨 tPA/neuroserpin 在 AD 发病机制中的潜在作用。AD 中 PAI-1 活性增加,这与 Aβ的积累有关。AD 神经病理学过程中 Aβ水平的逐渐增加与 PAI-1 的过度产生相关,随后导致纤溶酶和 tPA 活性降低。降低纤溶酶和 tPA 活性会通过减少 Aβ清除来促进 Aβ的积累。神经丝氨酸蛋白酶抑制剂在 AD 的发病机制中起着关键作用,因为它调节 Aβ的表达和积累。神经丝氨酸蛋白酶抑制剂表达增加会抑制具有神经保护作用的 tPA 和纤溶酶的产生,随后导致 Aβ的清除减少。这些观察结果对神经丝氨酸蛋白酶抑制剂是否具有神经保护作用或是否参与 AD 进展提出了相互矛盾的证据。因此,tPA 表达减少伴随着神经丝氨酸蛋白酶抑制剂的过度表达可能会促进 AD 神经病理学的发展。